Promoting Growth Across Diverse
Patient Long-Term Capital Base
Focused on buying and building businesses over the long-term, without the external pressure to exit our investments at a pre-defined time period
Building
Founded in 2012, StoneCalibre is an international private investment firm with offices located in Los Angeles, Paris and London.
We are focused on corporate divestitures, buy & builds and special situations opportunities via control transactions. To date, we have acquired 70 companies throughout North America and Europe through 7 different investment platforms. While we are a generalist investor, we have relevant expertise in the following sectors:
Non-Core, Non-Strategic Assets
Complex Carve-Outs
Product Line Divestiture
Regulatory Driven Sale Processes
Timing Considerations
Post-Closing Partnerships
Platform in a Fragmented Industry
Organic and Inorganic Growth
International Consolidation
Vertical or Horizontal Expansion
Integrations
Operational Turnaround
Legacy Products
Declining Revenue
Secular Decline
Financial Restructuring
Storied Credits
Focused on buying and building businesses over the long-term, without the external pressure to exit our investments at a pre-defined time period
Having completed numerous carve-outs from Fortune 500 companies, we are capable of navigating the complexities that arise in any transaction and structuring creative solutions to ensure mutually desirable outcomes
Decades of experience executing M&A transactions, including entrepreneur-owned companies, public to private transactions and corporate divestitures across a myriad of industries
Able to deploy the necessary resources to conduct our due diligence review in a manner that minimizes any disruption to the Company, while working to consummate a transaction within a timeline that meets the seller’s expectations
StoneCalibre views employees as the most critical asset of any investment. We align the long-term interests of management and employees with that of our own
Understanding of the importance for both the sale process and the transition to new ownership to be handled in an appropriate manner such that the personal or corporate brand equity of the Seller remains intact
Our investment approach is based upon creating value from deal origination through to monetization. Pre-acquisition, our process is focused on finding companies that possess certain characteristics which in our view can lead to long-term value creation. Then, it involves structuring the right transaction to position the company for long-term success while meeting the seller’s objectives. Immediately post-acquisition, we support the management team with the internal and external resources to help them execute on the value creation strategies identified during the diligence process. The management team owns all growth and operational improvement initiatives while leveraging StoneCalibre’s role through the transition to new ownership and beyond as an engaged Board partner. As part of our value creation focus, we rely on the following principles:
The StoneCalibre team comprises a diverse group of professionals who are highly experienced in both investment execution and long-term value creation. Supported by patient long-term capital, our international team of deal originators, investment professionals and operating partners pursue a cohesive and collaborative approach of working with management teams to ensure every investment achieves its full potential.
January 17, 2024
Industry: Life Sciences
January 15, 2024
Industry: Life Sciences
January 22, 2024
Industry: Life Sciences
January 8, 2024
Industry: Life Sciences
January 2, 2024
Industry: Life Sciences
December 11, 2023
Industry: Life Sciences
November 27, 2023
Industry: Life Sciences
August 19, 2024
Industry: Life Sciences
August 14, 2024
Industry: Life Sciences
August 7, 2024
Industry: Life Sciences
June 19, 2024
Industry: Life Sciences
June 17, 2024
Industry: Life Sciences
April 29, 2024
Industry: Life Sciences
March 4, 2024
Industry: Life Sciences
January 17, 2024
Industry: Life Sciences
January 15, 2024
Industry: Life Sciences
January 22, 2024
Industry: Life Sciences
January 8, 2024
Industry: Life Sciences
January 2, 2024
Industry: Life Sciences
December 11, 2023
Industry: Life Sciences
November 27, 2023
Industry: Life Sciences
August 19, 2024
Industry: Life Sciences
August 14, 2024
Industry: Life Sciences
August 7, 2024
Industry: Life Sciences
June 19, 2024
Industry: Life Sciences
June 17, 2024
Industry: Life Sciences
April 29, 2024
Industry: Life Sciences
March 4, 2024
Industry: Life Sciences